Developer docs
API playgroundTry for free, no card

Search company profiles

Leadiant Biosciences

Full company profile

uuid00096sv

Namestring
Leadiant Biosciences
Legal namestring
Leadiant Biosciences, Inc.
Websiteurl
leadiant.com
Company typeenum
Private
Founded yearint
1984
Descriptiontext

Leadiant Biosciences, Inc. is a privately held U.S. specialty pharmaceutical company focused exclusively on rare and ultra-rare diseases. Founded with a heritage in orphan drug development — receiving its initial U.S. Orphan Drug Designation in 1984 as the fourth company in the world to do so — the company develops, registers, and commercializes therapies for patients with limited or no treatment options. It is wholly owned by Essetifin S.p.A., a Rome-based holding company, and operates from a 251–500 employee base headquartered at 530 Gaither Rd., Suite 300, Rockville, Maryland, with wholly-owned subsidiaries in the United Kingdom, France, and Germany, plus a Canada office.

The company's commercial portfolio consists of three FDA-approved prescription products addressing distinct rare disease franchises: Carnitor (levocarnitine) for primary and secondary carnitine deficiency, with tablet, oral solution, sugar-free oral solution, and injectable formulations; Cystaran (cysteamine ophthalmic solution 0.44%) for corneal cystine crystal accumulation in cystinosis patients; and Matulane (procarbazine hydrochloride capsules) for Hodgkin Lymphoma. These products are supported by ongoing R&D programs and patient-focused support services. Distribution is conducted through specialty pharmacy channels, including an exclusive arrangement with Walgreens Specialty Pharmacy for Matulane, alongside direct phone-based ordering infrastructure for healthcare providers and patient assistance/reimbursement support programs.

The go-to-market model is sales-led and centered on healthcare professional engagement, patient advocacy partnerships (EveryLife Foundation for Rare Diseases, Global Genes, NORD, Cystinosis Research Foundation/Network, NIH-linked organizations, and the American Cancer Society), and educational content marketing aimed at patients, caregivers, and clinicians. The privately held structure under Essetifin S.p.A. allows prioritization of patient outcomes over quarterly shareholder returns, and the company maintains sector compliance with the PhRMA Code on Interactions with Healthcare Professionals and California Health & Safety Code §§119400–119402. Revenue mechanics are based on branded specialty pharmaceutical product sales rather than licensing or platform economics, and pricing is not publicly disclosed.

Short descriptiontext

Leadiant Biosciences is a privately held U.S. specialty pharmaceutical company developing and commercializing FDA-approved rare disease therapies (Carnitor, Cystaran, Matulane) for patients with metabolic, ophthalmologic, and oncologic conditions, owned by Essetifin S.p.A.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGaithersburg, United States
HQ citystring
Gaithersburg
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, orphan drug development, specialty pharmaceuticals, enzyme replacement therapy, prescription drug manufacturing
Industry3 codes
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals (Rare Disease)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Leadiant Biosciences generates revenue through the sale of prescription pharmaceutical products for rare diseases. The company markets and distributes three FDA-approved products: Carnitor (levocarnitine), Cystaran (cysteamine ophthalmic solution), and Matulane (procarbazine hydrochloride). Products are distributed through specialty pharmacy channels.

leadiant.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Carnitor®
Description

Levocarnitine product for treatment of primary systemic carnitine deficiency and secondary carnitine deficiency

leadiant.com
+2 more records
Core offering1 text field

Leadiant Biosciences is a U.S. research-based pharmaceutical company that develops, registers, and commercializes therapies for patients affected by rare diseases. Its marketed portfolio consists of three FDA-approved prescription products: Carnitor (levocarnitine) for primary and secondary carnitine deficiency, Cystaran (cysteamine ophthalmic solution) 0.44% for corneal cystine crystal accumulation in cystinosis patients, and Matulane (procarbazine hydrochloride) for Hodgkin Lymphoma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Cystinosis affects one in 100,000-200,000 live births in the United States
+2 more records
Product overview1 text field

Leadiant Biosciences is a U.S. research-based pharmaceutical company focused on rare diseases. The company's product portfolio consists of three FDA-approved prescription medications: Carnitor® (levocarnitine) for carnitine deficiency disorders; Cystaran® (cysteamine ophthalmic solution) for corneal cystine crystal accumulation in cystinosis patients; and Matulane® (procarbazine hydrochloride) for Hodgkin Lymphoma. These products address rare genetic and metabolic diseases affecting patients across different therapeutic areas including metabolic disorders, ophthalmology, and oncology.

Product and service3 records
1Carnitor (levocarnitine)
CategoryRare Disease Therapeutics
Description

Levocarnitine supplement available in Tablets, Oral Solution, Sugar-Free Oral Solution, and Injection formulations for the treatment of primary systemic carnitine deficiency, acute and chronic treatment of secondary carnitine deficiency in patients with inborn errors of metabolism, and prevention/treatment of carnitine deficiency in patients with end-stage renal disease undergoing dialysis. Targeted at healthcare providers treating patients with metabolic carnitine deficiency disorders.

2Cystaran (cysteamine ophthalmic solution) 0.44%
CategoryRare Disease Therapeutics
Description

A cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis. Targeted at ophthalmologists and other healthcare providers managing cystinosis patients.

3Matulane (procarbazine hydrochloride)
CategoryRare Disease Therapeutics
Description

Procarbazine hydrochloride capsules indicated for the treatment of Hodgkin Lymphoma. Targeted at oncologists and hematology/oncology healthcare providers. Distributed exclusively through Walgreens Specialty Pharmacy.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierSupportTypeOthers
Description

Patient advocacy organization partnering with Leadiant to raise awareness and improve understanding of rare and ultra-rare diseases. Provides informational and educational resources for patients and families.

Strategic tierSupportTypeOthers
Description

Rare disease advocacy organization collaborating with Leadiant to support patients and families affected by rare diseases through education and awareness initiatives.

Strategic tierSupportTypeOthers
Description

National organization providing advocacy and resources for rare disease patients, partnering with Leadiant to support the rare disease community.

Strategic tierSupportTypeOthers
Description

Disease-specific advocacy organization supporting cystinosis patients and families, partnering with Leadiant for cystinosis awareness and education.

5Cystinosis Research Network
Strategic tierSupportTypeOthers
Description

Patient advocacy organization focused on cystinosis, providing support and resources for affected families in collaboration with Leadiant.

leadiant.com
Strategic tierSupportTypeOthers
Description

Federal research institution providing educational resources and information on rare diseases including cystinosis, carnitine deficiency, and Hodgkin Lymphoma through various institutes including GARD, National Eye Institute, and National Cancer Institute.

7American Cancer Society
Strategic tierSupportTypeOthers
Description

Cancer advocacy organization providing resources and information for Hodgkin Lymphoma patients, partnering with Leadiant for patient education.

leadiant.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BioMarin is a rare disease specialty pharmaceutical company developing enzyme replacement and gene therapies for ultra-rare genetic disorders. Comparable business model focused on small patient populations, orphan drug exclusivity, and specialty distribution.

TypeDirect peer
Description

Jazz Pharmaceuticals is a specialty pharma focused on rare neurological and oncology indications, including hematology assets comparable to Matulane. Similar commercial model targeting niche prescriber bases via specialty channels.

TypeDirect peer
Description

Alexion pioneered rare disease drug development with Soliris and Strensiq, using the same orphan drug regulatory pathway Leadiant has leveraged since 1984. Directly comparable specialty pharma business model targeting ultra-rare diseases.

TypeDirect peer
Description

Recordati Rare Diseases markets CYSTADROPS (cysteamine eye drops), a direct competitor to Leadiant's Cystaran in cystinosis. Both companies focus on rare metabolic and genetic diseases with specialty distribution models.

TypeDirect peer
Description

Ultragenyx develops and commercializes therapies for rare and ultra-rare genetic diseases, often with small patient populations and enzyme or biologics-based modalities paralleling Leadiant's rare disease focus.

TypeDirect peer
Description

Sobi is a European-headquartered specialty pharma focused on rare diseases, with operations across immunology, genetic diseases, and specialty care. Similar multi-geography footprint and orphan drug expertise as Leadiant.

TypeBroad incumbent
Description

Sanofi's Genzyme unit is a major rare disease franchise with enzyme replacement therapies (e.g., Cerezyme, Fabrazyme). Broader portfolio than Leadiant but operates the same specialty distribution, patient services, and orphan drug regulatory playbook.

8Horizon Therapeutics (Amgen)
TypeDirect peer
Description

Horizon (now part of Amgen) markets PROCYSBI, a competing cysteamine therapy for cystinosis. Horizon's broader rare disease specialty pharma model (orphan drugs, patient services, specialty distribution) directly parallels Leadiant's approach.

TypeDirect peer
Description

Chiesi Global Rare Diseases (formed via acquisition of Amryt Pharma) is a specialty pharma focused on rare metabolic and endocrine disorders, closely matching Leadiant's therapeutic area mix including enzyme replacement therapies.

TypeOthers
Description

Walgreens Specialty Pharmacy is Leadiant's exclusive distribution partner for Matulane and a key channel for Cystaran. Not a competitor but a critical channel partner whose economics directly affect Leadiant's product access and reimbursement realization.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Leadiant Biosciences

Specialty Pharmaceuticals (Rare Disease)leadiant.com

Leadiant Biosciences is a privately held U.S. specialty pharmaceutical company developing and commercializing FDA-approved rare disease therapies (Carnitor, Cystaran, Matulane) for patients with metabolic, ophthalmologic, and oncologic conditions, owned by Essetifin S.p.A.

What Leadiant Biosciences does

Leadiant Biosciences, Inc. is a privately held U.S. specialty pharmaceutical company focused exclusively on rare and ultra-rare diseases. Founded with a heritage in orphan drug development — receiving its initial U.S. Orphan Drug Designation in 1984 as the fourth company in the world to do so — the company develops, registers, and commercializes therapies for patients with limited or no treatment options. It is wholly owned by Essetifin S.p.A., a Rome-based holding company, and operates from a 251–500 employee base headquartered at 530 Gaither Rd., Suite 300, Rockville, Maryland, with wholly-owned subsidiaries in the United Kingdom, France, and Germany, plus a Canada office.

The company's commercial portfolio consists of three FDA-approved prescription products addressing distinct rare disease franchises: Carnitor (levocarnitine) for primary and secondary carnitine deficiency, with tablet, oral solution, sugar-free oral solution, and injectable formulations; Cystaran (cysteamine ophthalmic solution 0.44%) for corneal cystine crystal accumulation in cystinosis patients; and Matulane (procarbazine hydrochloride capsules) for Hodgkin Lymphoma. These products are supported by ongoing R&D programs and patient-focused support services. Distribution is conducted through specialty pharmacy channels, including an exclusive arrangement with Walgreens Specialty Pharmacy for Matulane, alongside direct phone-based ordering infrastructure for healthcare providers and patient assistance/reimbursement support programs.

The go-to-market model is sales-led and centered on healthcare professional engagement, patient advocacy partnerships (EveryLife Foundation for Rare Diseases, Global Genes, NORD, Cystinosis Research Foundation/Network, NIH-linked organizations, and the American Cancer Society), and educational content marketing aimed at patients, caregivers, and clinicians. The privately held structure under Essetifin S.p.A. allows prioritization of patient outcomes over quarterly shareholder returns, and the company maintains sector compliance with the PhRMA Code on Interactions with Healthcare Professionals and California Health & Safety Code §§119400–119402. Revenue mechanics are based on branded specialty pharmaceutical product sales rather than licensing or platform economics, and pricing is not publicly disclosed.

Leadiant Biosciences firmographics

Firmographics
Name
Leadiant Biosciences
Legal name
Leadiant Biosciences, Inc.
Website
https://leadiant.com
Company type
Private
Founded year
1984
Operating status
Operating
Headcount range
11–50 employees
Short description
Leadiant Biosciences is a privately held U.S. specialty pharmaceutical company developing and commercializing FDA-approved rare disease therapies (Carnitor, Cystaran, Matulane) for patients with metabolic, ophthalmologic, and oncologic conditions, owned by Essetifin S.p.A.
Ownership category
akta.pro rank

Leadiant Biosciences industry classification

Industry
Product category
Specialty Pharmaceuticals (Rare Disease)
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Orphan drug development
  • Specialty pharmaceuticals
  • Enzyme replacement therapy
  • Prescription drug manufacturing

Where Leadiant Biosciences is headquartered

Location

Headquarters

HQ city
Gaithersburg
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Leadiant Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Leadiant Biosciences generates revenue through the sale of prescription pharmaceutical products for rare diseases. The company markets and distributes three FDA-approved products: Carnitor (levocarnitine), Cystaran (cysteamine ophthalmic solution), and Matulane (procarbazine hydrochloride). Products are distributed through specialty pharmacy channels.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Leadiant Biosciences product offering

Product offering

Core offering

Leadiant Biosciences is a U.S. research-based pharmaceutical company that develops, registers, and commercializes therapies for patients affected by rare diseases. Its marketed portfolio consists of three FDA-approved prescription products: Carnitor (levocarnitine) for primary and secondary carnitine deficiency, Cystaran (cysteamine ophthalmic solution) 0.44% for corneal cystine crystal accumulation in cystinosis patients, and Matulane (procarbazine hydrochloride) for Hodgkin Lymphoma.

Product overview

Leadiant Biosciences is a U.S. research-based pharmaceutical company focused on rare diseases. The company's product portfolio consists of three FDA-approved prescription medications: Carnitor® (levocarnitine) for carnitine deficiency disorders; Cystaran® (cysteamine ophthalmic solution) for corneal cystine crystal accumulation in cystinosis patients; and Matulane® (procarbazine hydrochloride) for Hodgkin Lymphoma. These products address rare genetic and metabolic diseases affecting patients across different therapeutic areas including metabolic disorders, ophthalmology, and oncology.

Differentiator

Problem solved

Functional benefit

Brands

  • Carnitor®: Levocarnitine product for treatment of primary systemic carnitine deficiency and secondary carnitine deficiency
  • Cystaran®
  • Matulane®

Products and services

  • Carnitor (levocarnitine) Levocarnitine supplement available in Tablets, Oral Solution, Sugar-Free Oral Solution, and Injection formulations for the treatment of primary systemic carnitine deficiency, acute and chronic treatment of secondary carnitine deficiency in patients with inborn errors of metabolism, and prevention/treatment of carnitine deficiency in patients with end-stage renal disease undergoing dialysis. Targeted at healthcare providers treating patients with metabolic carnitine deficiency disorders.
  • Cystaran (cysteamine ophthalmic solution) 0.44% A cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis. Targeted at ophthalmologists and other healthcare providers managing cystinosis patients.
  • Matulane (procarbazine hydrochloride) Procarbazine hydrochloride capsules indicated for the treatment of Hodgkin Lymphoma. Targeted at oncologists and hematology/oncology healthcare providers. Distributed exclusively through Walgreens Specialty Pharmacy.

Quantifiable outcome

  • Cystinosis affects one in 100,000-200,000 live births in the United States
  • +2 more outcomes

Companies that use Leadiant Biosciences

Customer profile

Segments2 records

Ideal customer profiles2 records

Leadiant Biosciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Leadiant Biosciences partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered support.

  • EveryLife Foundation for Rare DiseasessupportOthersPatient advocacy organization partnering with Leadiant to raise awareness and improve understanding of rare and ultra-rare diseases. Provides informational and educational resources for patients and families.
  • Global GenessupportOthersRare disease advocacy organization collaborating with Leadiant to support patients and families affected by rare diseases through education and awareness initiatives.
  • National Organization for Rare Disorders (NORD)supportOthersNational organization providing advocacy and resources for rare disease patients, partnering with Leadiant to support the rare disease community.
  • Cystinosis Research FoundationsupportOthersDisease-specific advocacy organization supporting cystinosis patients and families, partnering with Leadiant for cystinosis awareness and education.
  • Cystinosis Research NetworksupportOthersPatient advocacy organization focused on cystinosis, providing support and resources for affected families in collaboration with Leadiant.
  • National Institutes of Health (NIH)supportOthersFederal research institution providing educational resources and information on rare diseases including cystinosis, carnitine deficiency, and Hodgkin Lymphoma through various institutes including GARD, National Eye Institute, and National Cancer Institute.
  • American Cancer SocietysupportOthersCancer advocacy organization providing resources and information for Hodgkin Lymphoma patients, partnering with Leadiant for patient education.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Leadiant Biosciences competitors and assessment

Company assessment

Direct peers

  • BioMarin Pharmaceutical: BioMarin is a rare disease specialty pharmaceutical company developing enzyme replacement and gene therapies for ultra-rare genetic disorders. Comparable business model focused on small patient populations, orphan drug exclusivity, and specialty distribution.
  • Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty pharma focused on rare neurological and oncology indications, including hematology assets comparable to Matulane. Similar commercial model targeting niche prescriber bases via specialty channels.
  • Alexion (AstraZeneca Rare Disease): Alexion pioneered rare disease drug development with Soliris and Strensiq, using the same orphan drug regulatory pathway Leadiant has leveraged since 1984. Directly comparable specialty pharma business model targeting ultra-rare diseases.
  • Recordati Rare Diseases: Recordati Rare Diseases markets CYSTADROPS (cysteamine eye drops), a direct competitor to Leadiant's Cystaran in cystinosis. Both companies focus on rare metabolic and genetic diseases with specialty distribution models.
  • Ultragenyx Pharmaceutical: Ultragenyx develops and commercializes therapies for rare and ultra-rare genetic diseases, often with small patient populations and enzyme or biologics-based modalities paralleling Leadiant's rare disease focus.
  • Swedish Orphan Biovitrum (Sobi): Sobi is a European-headquartered specialty pharma focused on rare diseases, with operations across immunology, genetic diseases, and specialty care. Similar multi-geography footprint and orphan drug expertise as Leadiant.
  • Horizon Therapeutics (Amgen): Horizon (now part of Amgen) markets PROCYSBI, a competing cysteamine therapy for cystinosis. Horizon's broader rare disease specialty pharma model (orphan drugs, patient services, specialty distribution) directly parallels Leadiant's approach.
  • Chiesi Global Rare Diseases: Chiesi Global Rare Diseases (formed via acquisition of Amryt Pharma) is a specialty pharma focused on rare metabolic and endocrine disorders, closely matching Leadiant's therapeutic area mix including enzyme replacement therapies.

Broad incumbents

  • Sanofi Genzyme (Rare Diseases): Sanofi's Genzyme unit is a major rare disease franchise with enzyme replacement therapies (e.g., Cerezyme, Fabrazyme). Broader portfolio than Leadiant but operates the same specialty distribution, patient services, and orphan drug regulatory playbook.

Others

  • Walgreens Specialty Pharmacy: Walgreens Specialty Pharmacy is Leadiant's exclusive distribution partner for Matulane and a key channel for Cystaran. Not a competitor but a critical channel partner whose economics directly affect Leadiant's product access and reimbursement realization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Leadiant Biosciences social profiles

Digital presence

Leadiant Biosciences compliance and trust

Trust signal

Compliance2 records

Leadiant Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Leadiant Biosciences leadership team

Management profile

Number of profiles

Profiles5 records

Leadiant Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Leadiant Biosciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Leadiant Biosciences M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Leadiant Biosciences

What does Leadiant Biosciences do?

Leadiant Biosciences is a U.S. research-based pharmaceutical company that develops, registers, and commercializes therapies for patients affected by rare diseases. Its marketed portfolio consists of three FDA-approved prescription products: Carnitor (levocarnitine) for primary and secondary carnitine deficiency, Cystaran (cysteamine ophthalmic solution) 0.44% for corneal cystine crystal accumulation in cystinosis patients, and Matulane (procarbazine hydrochloride) for Hodgkin Lymphoma.

Is Leadiant Biosciences a public or private company?

Leadiant Biosciences is a private company. It is classified as corporate owned and is currently operating.

When was Leadiant Biosciences founded?

Leadiant Biosciences was founded in 1984. It employs 11 to 50 people.

Where is Leadiant Biosciences based?

Leadiant Biosciences is headquartered in Gaithersburg, United States, in the North America region.

How does Leadiant Biosciences make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Leadiant Biosciences's main competitors?

Direct peers on record are BioMarin Pharmaceutical, Jazz Pharmaceuticals, Alexion (AstraZeneca Rare Disease), Recordati Rare Diseases, Ultragenyx Pharmaceutical, Swedish Orphan Biovitrum (Sobi), Horizon Therapeutics (Amgen) and Chiesi Global Rare Diseases. Sanofi Genzyme (Rare Diseases) is listed as a broad incumbent. Walgreens Specialty Pharmacy is listed as an others.

Does Leadiant Biosciences have an API?

No public API is recorded for Leadiant Biosciences.

What industry is Leadiant Biosciences in?

Leadiant Biosciences's product category is Specialty Pharmaceuticals (Rare Disease). Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIAIAK, Rare Ophthalmology Disorder Therapies. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireAdagen (Leadiant Biosciences) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035FResearchAndMarkets.com has published the Adagen Market Report 2026, projecting the Adagen market value to rise from $0.09 million in 2025 to $0.13 million by 2030, driven by factors including the lack of alternative therapies for ADA-SCID, orphan drug incentives, and advancements in genetic screening. Leadiant Biosciences Inc. is identified as a prominent player in the Adagen market, with North America leading in 2025 and Asia-Pacific identified as the fastest-growing region. The report highlights key trends including sustained use in rare immunodeficiency disorders, emphasis on enzyme replacement therapies, and increasing integration of precision medicine in rare disease treatment.BioSpaceHealth Canada Approves Cysklar® (Cysteamine Ophthalmic Solution) 0.44% for Treatment of Corneal Crystals in People with CystinosisHealth Canada approved Cysklar (cysteamine ophthalmic solution) 0.44% for treating corneal cystine crystal accumulation in people with cystinosis. The approval offers a new therapeutic option for Canadian patients, with Leadiant Biosciences committed to informing them about availability.PR NewswireGlobal Elapegademase-lvlr Market to be Worth US$16.9 Mn by 2025 as Diagnostics Improve - QY ResearchQY Research published a market report on the global elapegademase-lvlr drug market, valued at US$11 million in 2018 and projected to reach US$16.9 million by 2025, growing at a compound annual growth rate of 3.5%. The drug, marketed as Revcovi, is used to treat adenosine deaminase severe combined immune deficiency (ADA-SCID), an inherited immune disorder affecting both pediatric and adult patients. Leadiant Biosciences received FDA approval for Revcovi, enabling the treatment to replace the predecessor drug Adagen as a more reliable enzyme therapy option.PR NewswireExeGi Wins Court Ruling Against VSL#3®*, Permanent Injunction Blocks False Advertising To Doctors, ConsumersOn June 21, 2019, the United States District Court for the District of Maryland ruled in favor of ExeGi Pharma LLC and inventor Professor Claudio De Simone, affirming a November 2018 jury verdict that awarded over $18 million in damages against VSL Pharmaceuticals Inc., Leadiant Biosciences, and Alfasigma USA, Inc. for false advertising under the Lanham Act. The court found that the defendants reverse-engineered and launched an imitation of De Simone's original probiotic formulation (originally sold as VSL#3) without informing patients or physicians, and issued a permanent injunction preventing them from linking their product to the original formulation or citing clinical studies conducted only on the original formulation. The ruling concludes over four years of litigation and is intended to protect patients depending on the original formulation, now sold as VISBIOME®.PR NewswireTraceLink Unveils Industry Speakers for FutureLink Munich, Including Leaders from Santen, Leadiant Biosciences, NHS and MenariniTraceLink announced the lineup of industry speakers for its upcoming FutureLink Munich conference, scheduled for June 6-7, 2018. The event focuses on EU FMD compliance and digital drug supply networks, featuring presentations from leaders at pharmaceutical companies including Santen, Menarini, Leadiant Biosciences, and NHS Improvement.